Roche will acquire Poseida Therapeutics for $1 billion, aiming to develop allogeneic cell therapies for solid tumors and immunological indications. This deal includes an upfront payment of $9 per share, with potential additional payments of up to $4 per share based on program goals. Poseida specializes in non-viral technologies for cell and gene therapies, with promising therapies targeting multiple myeloma and B-cell malignancies. Roche sees potential in Poseida’s research and hopes to advance cell therapies in oncology, immunology, and neurology. The acquisition is expected to be completed in the first quarter of 2025.
Source link
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
